Titre du document / Document title

Alphagan allergy may increase the propensity for multiple eye-drop allergy

Auteur(s) / Author(s)

OSBORNE S. A. ⁽¹⁾ ; MONTGOMERY D. M. I. ⁽¹⁾ ; MORRIS D. ⁽¹⁾ ; MCKAY I. C. ⁽¹⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ North Glasgow University Hospitals, NHS Trust, ROYAUME-UNI

Résumé / Abstract

Aims Since its introduction in 1996, brimonidine tartrate 0.2% ophthalmic solution (Alphagan, Allergan) twice daily has become established as an effective intra ocular pressure-lowering treatment. While the efficacy of Alphagan cannot be questioned, we gained the clinical impression that the drug has an unacceptably high rate of allergy. Of greater concern, we suspected that patients suffering from local Alphagan allergy had a higher rate of allergy to subsequently used topical preparations. We analysed data from a large scale study of glaucoma patients to establish whether our suspicions were correct. Subjects and methods We have created a database of the entire glaucoma treatment histories for consecutive patients attending a single consultant's clinics (DMIM) at Glasgow Royal Infirmary between May 1999 and September 2001. All have undergone medical treatment for primary open angle glaucoma, ocular hypertension, or normal tension glaucoma. Patients with any other form of glaucoma, and patients in whom a full record of treatment was not available were excluded from the study. Results Alphagan was discontinued due to allergy on 73 per 100000 patient treatment days. This was a far higher frequency than for other preparations. In patients allergic to both Alphagan and another preparation (Timoptol, Trusopt and Xalatan), the mean interval between the first and second allergy was shorter when Alphagan allergy occurred first. This was statistically significant in Timoptol and Trusopt cross-reactivity. Conclusions Alphagan has high allergenicity, and may increase the likelihood of allergy to subsequently used preparations.

Revue / Journal Title

Eye   ISSN 0950-222X   CODEN EYEEEC 

Source / Source

2005, vol. 19, n^o2, pp. 129-137 [9 page(s) (article)] (7 ref.)

Langue / Language

Anglais

Editeur / Publisher

Nature Publishing Group, Basingstoke, ROYAUME-UNI  (1987) (Revue)

Mots-clés anglais / English Keywords

Eye disease ; α-Adrenergic receptor agonist ; α2-Adrenergic receptor ; Quinoxaline derivatives ; Imidazole derivatives ; Agonist ; Immunopathology ; Protozoa ; Ciliata ; Ophthalmology ; Glaucoma ; Hypersensitivity ; Antiglaucomatous agent ; Brimonidine ; Eye drop ; Glaucoma (eye) ; Multiple ; Increase ; Allergy ;

Mots-clés français / French Keywords

Oeil pathologie ; Stimulant α-adrénergique ; Récepteur α2-adrénergique ; Quinoxaline dérivé ; Imidazole dérivé ; Agoniste ; Immunopathologie ; Protozoa ; Ciliata ; Ophtalmologie ; Glaucoma ; Hypersensibilité ; Antiglaucomateux ; Brimonidine ; Collyre ; Glaucome ; Multiple ; Augmentation ; Allergie ;

Mots-clés espagnols / Spanish Keywords

Ojo patología ; Estimulante α-adrenérgico ; Receptor α2-adrenérgico ; Quinoxalina derivado ; Imidazol derivado ; Agonista ; Inmunopatología ; Protozoa ; Ciliata ; Oftalmología ; Glaucoma ; Hipersensibilidad ; Antiglaucomatoso ; Brimonidina ; Colirio ; Glaucoma (ojo) ; Múltiple ; Aumentación ; Alergia ;

Mots-clés d'auteur / Author Keywords

alphagan ; brimonidine ; allergy ; hypersensitivity ; glaucoma ;

Localisation / Location

INIST-CNRS, Cote INIST : 21076, 35400012672029.0030